A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 712-717

  Pitot, Henry C ^a   Reid, Joel M ^a   Sloan, Jeff A ^a   Ames, Matthew M ^a   Adjei, Alex A ^a   Rubin, Joseph ^a   Bagniewski, Pamela G ^a   Atherton, Pamela ^a   Rayson, Daniel ^a   Goldberg, Richard M ^a   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOZELESIN; BIZELESIN; CARZELESIN; INDOLE DERIVATIVE; NSC 615291; RACHELMYCIN; U 77809; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; FEMALE; HUMAN; LEUKOCYTE; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPHILS; UREA;

EID: 0036304763     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. CC-1065 (NSC-298223), a new antitumor antibiotic production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism
2. Structure of CC-1065 (NSC-298223), a new antitumor antibiotic
3. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779
4. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065
5. CC-1065 analogs: Therapeutic potential of a sequence specific drug-DNA reaction
6. Phase I study of adozelesin (U-73,975) in patients with solid tumors
7. DNA interstrand cross-linking, DNA sequence specificity, and induced conformational changes produced by a dimeric analog of (+)-CC-1065
8. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065
9. Preclinical antitumor activity of bizelesin in mice
10. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells
11. Phase I study of carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
12. An analysis for variance test for normality
13. Weighted Kaplan-Meier statistics. Large sample and optimality considerations
14. A phase I trial of adozelesin, a novel DNA sequence-specific alkylating agent
15. Phase I trial of bizelesin using a single bolus infusion given every 28 days in patients with advanced cancer
16. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity
17. Evaluation of an L1210 bioassay and HPLC for determination of dolastatin-10 in human and murine plasma
18. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors